Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.67 |
| ▸ | CTSS | P25774 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28969869 | 1.00 | CTSK (0.67) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL24097543 | 0.91 | CTSK (0.63) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL28969867 | 0.87 | CTSK (0.51) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL28969873 | 0.87 | CTSS (0.69) | CTSKCTSSCA2TDP1CAPN1 | |
| SCHEMBL5873406 | 0.86 | CTSK (0.65) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL13921027 | 0.86 | CTSK (0.65) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL20046440 | 0.86 | CTSK (0.65) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL7754405 | 0.86 | CTSK (0.65) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL13921005 | 0.86 | CTSK (0.65) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL28969855 | 0.86 | CTSK (0.65) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265096-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1567169-A2 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040142857-A1 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004041203-A2 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142857-A1 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | TYMP, GDA, GCG | CTSK 1533/4885CTSS 1486/4885CA2 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.